Condensed Financial Information (Parent Company Only) - Schedule of Condensed Statements of Cash Flows Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating Activities:
Net loss attributable to Alignment Healthcare, Inc.	$ (128,035)	$ (148,017)	$ (149,547)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of debt issuance costs	1,293	1,254	1,850
Changes in operating assets and liabilities:
Net cash provided by (used in) operating activities	34,770	(59,187)	(45,427)
Investing Activities:
Investment in Subsidiary	(82,200)	(379,058)	(2,825)
Net cash provided by (used in) investing activities	39,191	(147,263)	(28,217)
Financing Activities:
Shares withheld net of restricted stock	(350)	0	0
Stock options exercised	155	0	0
Proceeds from long-term debt	380,000	0	165,000
Debt issuance costs	(8,792)	0	(5,196)
Net cash provided by financing activities	156,028	105	16,593
Net (decrease) increase in cash	229,989	(206,345)	(57,051)
Cash, cash equivalents and restricted cash at beginning of period	204,954	411,299	468,350
Cash, cash equivalents and restricted cash at end of period	434,943	204,954	411,299
Supplemental non-cash financing and investing activities:
Debt issuance costs in accounts payable	512	0	0
Parent Company
Operating Activities:
Net loss attributable to Alignment Healthcare, Inc.	(128,035)	(148,017)	(149,547)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Equity in loss of subsidiary	125,892	147,529	149,109
Amortization of debt issuance costs	220	0	0
Changes in operating assets and liabilities:
Due to subsidiary	1,923	488	438
Net cash provided by (used in) operating activities	0	0	0
Investing Activities:
Investment in Subsidiary	(321,525)	0	0
Net cash provided by (used in) investing activities	(321,525)	0	0
Financing Activities:
Shares withheld net of restricted stock	(350)	0	0
Stock options exercised	155	0	0
Proceeds from long-term debt	330,000	0	0
Debt issuance costs	(8,280)	0	0
Net cash provided by financing activities	321,525	0	0
Net (decrease) increase in cash	0	0	0
Cash, cash equivalents and restricted cash at beginning of period	0	0	0
Cash, cash equivalents and restricted cash at end of period	0	0	0
Supplemental non-cash financing and investing activities:
Contribution of equity to subsidiary related to equity-based compensation	71,132	66,835	81,718
Distribution from subsidiary	0	0	85
Debt issuance costs in accounts payable	$ 512	$ 0	$ 0